BCMNY
TEVA icon

Buckingham Capital Management (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Buckingham Capital Management (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-122,688
Closed -$4.81M – 100
2013
Q2 		$4.81M Buy
+122,688
New +$4.78M 0.46% 76

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Buckingham Capital Management (New York)'s TEVA Position: Q3 2013 in Review

Buckingham Capital Management (New York) sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 122,688 shares — an estimated $4.81M sold.

Buckingham Capital Management (New York) first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $4.81M in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Buckingham Capital Management (New York) reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Buckingham Capital Management (New York) sold 122,688 Teva Pharmaceuticals shares in Q3 2013, an estimated $4.81M.
  • Buckingham Capital Management (New York) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Buckingham Capital Management (New York)'s Teva Pharmaceuticals position peaked at $4.81M in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Buckingham Capital Management (New York)'s 13F filing for Q3 2013, filed 14 Nov 2013.